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ABSTRACT: 
Short interfering RNA (siRNA) is a class of nucleotide drugs with a profound potential to 
improve patient health through its ability to silence the expression of specific genes at the post-
transcriptional level.  However, the clinical application of siRNA therapeutics remains hindered 
by a lack of efficient delivery systems that deposit siRNA into the cytoplasm of cells, a step 
necessary for siRNA’s silencing effect.  Much research has focused on the development of 
siRNA delivery agents to overcome this challenge.  There are no standard pre-clinical models for 
testing of siRNA delivery agents, and investigators have chosen to evaluate efficacy in a variety 
of systems including in vitro tissue culture and animal models.  These systems have vastly 
different cellular microenvironments which may modulate cellular behavior and affect the 
response of cells to siRNA, thus altering the apparent efficacy of siRNA delivery agents.  The 
substrate on which cells adhere is one aspect of the microenvironment that has been previously 
shown to alter cellular behavior.  In this work, we tested the hypothesis that changing the 
properties of cellular adhesion substrates can change the apparent efficacy of a siRNA delivery 
agent.  Specifically, we used a commonly employed in vitro cationic lipid siRNA delivery vector 
and evaluated siRNA silencing efficacy in U251 cells seeded on alginate hydrogel surfaces.  
These surfaces were synthesized to have systematic variation in integrin ligand arginine-glycine-
aspartate (RGD) density and elastic modulus.  We found that an eightfold increase in RGD 
content of the alginate grown substrate increased siRNA knockdown efficacy from 25 ± 12% to 
52 ± 10%, with constant concentrations of siRNA and delivery agent.  We found no difference in 
siRNA mediated knockdown efficacy over the elastic modulus range tested (53-133 kPa).  These 
results indicate that the cell-adhesion substrate interaction can modulate siRNA protein silencing 
efficacy, a finding important for evaluation of siRNA therapeutics in the in vitro setting.   
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GLOSSARY 
 
AF488   Alexafluor488 
DMEM  Dulbecco's modified Eagles' medium 
DS    Degree of substitution 
EDTA   Ethylenediaminetetraacetic acid 
FACS    fluorescence-activated cell sorting 
eGFP    enhanced green fluorescent protein 
dsRNA  double stranded RNA 
PBS    phosphate buffered saline 
RGD    arginine-glycine-aspartate 
RISC    RNA-induced silencing complex 
RNAi    RNA interference 
shRNA  short hairpin RNA 
siRNA   short interfering RNA 
TCPS    tissue culture polystyrene   5 
 
INTRODUCTION 
This section provides motivation for exploring the interplay between cellular adhesion 
substrate and short interfering RNA (siRNA) efficacy.  It begins with an overview of siRNA, 
with a focus on the difficult delivery challenges that hinder its translation to the clinic.  
Subsequently, past work on adhesion substrate microenvironment induced alteration of cellular 
behavior is explored.  In particular, the role of two adhesion substrate properties - integrin ligand 
availability and mechanical stiffness- are covered in detail.  Alginate hydrogels are then 
introduced in order to justify use of this well validated model extracellular matrix system in the 
presented experiments.  Previous findings exploring the related phenomenon of alginate hydrogel 
adhesion substrate effects on DNA delivery is discussed in depth.  The section concludes with a 
brief description of this project’s aims in relationship to past findings.   
A brief history of short interfering RNA (siRNA) 
Driven by its immense promise of clinical usefulness, exploration of RNA interference 
(RNAi) has proceeded quickly in the last two decades.  Specifically, this promise lies in the 
ability of RNAi pathways to mediate potent and specific silencing of a particular protein’s 
expression through modulating the availability of mRNA for translation.  Because the morbidity 
and mortality associated with many diseases results from aberrant protein levels, the ability of 
RNAi based therapeutics to silence protein expression could alleviate symptoms and progression 
in a vast array of illnesses[1].  RNAi mechanisms have also found use in other areas where 
modulation of mRNA levels can alter cellular behavior including tissue engineering and 
developmental biology[2][3]. 
Today, RNAi mechanisms are considered ‘common knowledge’ and widely exploited in 
biological laboratories.  However, observations now attributed to RNAi initially puzzled 
researchers.  For instance, investigators in the early 1990’s attempted to enhance the depth of 6 
 
petunia petal color by introducing colored pigment genes.  Instead of yielding more deeply 
colored flowers, the investigators found the opposite.  Specifically, the generated flowers had 
areas of white on their petals where pigment production was completely inhibited.  Similarly 
unusual, unexplained findings were observed in other plant and animal studies[4][5].   It was not 
until Fire and Mello’s 1998 experiments on C. Elegans that an accurate hypothesis for this 
phenomenon was identified.  Specifically, they proposed that short pieces of double-stranded 
mRNA could operate post-transcriptionally to silence genes[6].  This hypothesis and their 
findings won them the 2006 Nobel Prize in Medicine, in addition to initiating the rapid 
development of the RNAi field[5].  With ensuing years, it has become clear that RNAi is an 
evolutionary ancient mechanism, conserved in many cells, including mammalian ones[7][8].  Via 
the RNAi pathway, it is possible for cells to down-regulate virtually any type of protein with 
high specificity and potency[9]. 
RNAi gene silencing mechanism 
Exploration into RNAi mechanisms is ongoing.  At the present time, the term RNAi is 
used to describe two types of post-transcriptional gene silencing: the normally exogenously 
induced short interfering RNA (siRNA) pathway and the endogenous microRNA pathway[9].  In 
the siRNA pathway, an Rnase III enzyme called Dicer recognizes long, annealed, double 
stranded RNA (dsRNA) and cleaves this dsRNA into smaller 21-nucleotide double stranded 
fragments called short interfering RNAs (siRNAs).  Subsequently, a protein RNA-induced 
silencing complex (RISC) containing Argonaute 2 (ARGO2 or EIF2C) recognizes and binds 
these RNA fragments[10].  The complex then mediates degradation of the siRNA sense strand 
and employs the retained anti-sense strand to identify mRNA molecules with complementary 
sequences.  Sequence specific mRNA recognition by the anti-sense strand containing RISC 7 
 
complex leads to cleavage of the mRNA, thus inhibiting downstream translation.  This cleavage 
occurs in a highly stereotyped manner between the mRNA nucleotides paired with positions 10 
and 11 on the guiding siRNA anti-sense strand, counting from the 5’ end.  After cleavage occurs, 
the siRNA anti-sense strand containing RISC complex is free to initiate another, new sequence 
specific round of mRNA cleavage.  As a result of this repeated process, a sharp attenuation in the 
protein expression encoded by the cleaved mRNA is observed. 
The second microRNA pathway of RNAi works through a similar mechanism of directed 
mRNA silencing.   However, in contrast to the siRNA pathway, the microRNA pathways involve 
a dsRNA with strands of mostly, but not complete, sequence complementarity, i.e. base pair 
mismatch is found within these dsRNAs.  This results in Dicer cleavage products of short RNA 
fragments possessing some mismatched base pairs with their target mRNA.  Investigations into 
the mechanisms of action are ongoing, but this low frequency of mismatching results 
predominantly in RISC complex mediated translational repression as opposed to direct mRNA 
degradation[11][12].   
Therapeutic application of RNAi 
Clearly, due to its ability to specifically silence gene expression, RNAi presents an 
attractive pathway for therapeutic intervention.  Most investigations into the exploitation of the 
RNAi pathway for clinical application have involved two major approaches.  The first approach 
involves delivery of a viral DNA vector designed to encode a specific sequence of mRNA that 
anneals with itself to form a hairpin loop structure.  This mRNA is called a short hairpin RNA 
(shRNA).  With the correct sequence design, the shRNA can be recognized and processed by the 
Dicer complex into active siRNA or microRNA components.  These components can then 
specifically repress protein expression via the mechanisms described previously.  The second 8 
 
approach involves the direct intracellular delivery of siRNA mimics.  In this approach, double 
stranded 21 nucleotide RNA fragments are used to exploit the RNAi pathway at the step of RISC 
recognition[9].  In theory, both pathways may lead to effective therapies.   
A variety of investigations at all stages are underway utilizing the RNAi mechanism.  
They include siRNA based treatments for cancers, neurodegenerative conditions and viral 
diseases, among a variety of different illness[13].  Targets for siRNA include pro-angiogenic 
factors, chemotherapeutic resistance factors and HIV encoded RNAs[14][15][16].  However, 
some controversy exists whether these applications are actually acting through RNAi based 
mechanisms or immune stimulatory mechanisms triggered non-specifically by exogenous 
nucleic acid exposure[17].   
Most would agree that the promise of RNAi based therapeutics has not yet been borne 
out in the clinic[18][19][20].  The most important challenge facing application of this technology 
is the development of effective delivery methods for either shRNA encoding DNA plasmids or 
siRNAs[21][6].  Nucleic acids are highly charged macromolecules that cannot easily pass 
through hydrophobic lipid bilayers.  For example, siRNA must reach the cytoplasm in order to 
interact with the RISC complex and mediate downstream silencing effects.  When introduced 
into the extracellular milieu, some portion of siRNAs is taken up via membrane bound cellular 
vesicles called endosomes.  However, siRNAs often remain sequestered within these endosomes 
due to the hydrophobic vesicle membrane perimeter.  As a result, they are unable to escape either 
the endosomal/lysosomal pathway leading to siRNA degradation or the recycling endosomal 
pathway leading to expulsion of siRNA back to the extracellular space[22].  Although virus 
derived delivery agents have shown experimental success in overcoming this endosomal 
entrapment barrier, skepticism regarding viral vector safety remains widespread.  This has 9 
 
resulted in increased focus on non-viral agents, including polymers, as delivery agents for 
siRNA.  Unfortunately, the transfection efficacy of non-viral agents still lags far behind that of 
viral ones[12][9].     
At the present, a substantial amount of work has been undertaken to understand the 
barriers facing the delivery of hydrophilic biomacromolecules like siRNA.  Experimentation has 
mainly focused on delivery vector design.  However, other factors exist that might control 
delivery effectiveness or the effectiveness of siRNA once delivered.  The cellular 
microenvironment, consisting of the surrounding in which a cell grows, is preeminent among 
these factors.  Furthermore, methods for evaluating siRNA delivery vectors have often in vitro 
substrates which may not closely resemble physiological microenvironments, possibly resulting 
in differential delivery vector efficacy when tested in an in vitro versus in vivo setting.   
  Substantial evidence exists demonstrating that cellular growth environments can 
significantly alter cellular behavior, including alterations important for biomacromolecule 
delivery.  These behaviors include ligand uptake and cellular proliferation[23].  In the following 
discussion, the work suggesting that microenvironment can alter cellular behavior, and by 
extension, the cellular response to biomacromolecular therapies, will be discussed in greater 
detail. 
The substrate on which cells grow influences cellular behavior 
Within the in vivo environment, the adhesion substrate immediately accessible by the cell 
consists primarily of extracellular matrix (ECM) components.  In both healthy and diseased 
physiological states, previous work has identified instances of ECM mediated changes in cellular 
behavior that may have potential downstream effects on siRNA efficacy.  For example, ECM can 
alter cellular proliferation.  Such an effect may influence the intracellular concentrations and thus 10 
 
the silencing potency of siRNA.  In addition, ECM and cell interactions can alter cellular 
responses to extracellular signaling molecules.  Because siRNA is also administered to the 
extracellular space, ECM mediated alterations in cellular behavior may also influence cellular 
response to siRNA.  Because these two properties of proliferation and extracellular signal 
response illuminate the possible role of adhesion substrate in siRNA delivery efficacy, selected 
examples from the literature are presented to illustrate adhesion substrate influence on these 
behaviors in greater detail. 
  In several different in vitro systems, both the density of adhesion moieties and 
mechanical stiffness of the adhesion substrate have been shown to alter cellular proliferation.  
Early on, it was observed that the presentation of ECM molecules, like fibronectin, could 
activate intracellular signaling cascades that induced the G0/G1 transition involved in cellular 
proliferation[24].  Investigation revealed that these signaling cascades were activated by cell 
surface receptors called integrins.  Integrins bind specific amino acid residues of the ECM, 
particularly the arg-gly-asp (RGD) amino acid sequence, and compose a large family of 
heterodimeric structured receptors.  The alpha and beta subunits of the heterodimer both posses 
transmembrane and cytoplasmic domains, allowing integrins to convey extracellular changes 
into the intracellular space[25].   Evidence has accumulated to suggest that integrin receptor 
clustering can induce increased cellular proliferation[23].  Thus, it is logical that the increased 
presence of RGD ligands within an ECM could induce integrin receptor clustering, resulting in 
increased cellular proliferation.  However, availability of integrin receptor ligands is not the only 
factor controlling proliferation.  Specifically, cells cultured on soft ECM gels that do not allow 
for cell spreading inhibited cell division despite high levels of RGD[26][27].  This suggests a 
role for mechanics of adhesion substrates in the initiation of integrin mediated cellular 11 
 
proliferation.  It has been now established that both RGD availability and adhesion substrate 
mechanics play important roles in triggering cellular proliferation.  For example, with 
hepatocytes, it was discovered that while integrin ligands alone are sufficient to promote the 
G0/G1 transition, entry into the S phase and proliferation required cell spreading- a phenomenon 
only possible on a substrate of adequate stiffness[28].  Findings demonstrating the importance of 
both RGD ligand density and adhesion substrate mechanics on the ability of cells to proliferate 
have been observed in other cell types as well, including pro-osteoblasts and myoblasts[29][30]. 
  A similar wealth of previous data exists to support the role of adhesion substrate in 
modulating cellular response to secreted ligands.  One example where the ECM plays a major in 
vivo role is via the development of the mammary gland.  Here the interplay between the 
developing epithelium and stroma directs epithelial responsiveness to secreted hormones.  
Specifically, it has been shown that mammary stroma (of the mammary fat pad) can induce 
estrogen-responsive progesterone receptor expression.  Through this mechanism, the mammary 
gland stroma stimulates and maintains the estrogen responsiveness of mammary epithelial cells.  
Similar examples can be found in diseased states[31].  There is accumulating evidence that 
abnormalities of ECM amount and composition are associated with the development of 
malignancy.  It has been suggested that these alterations may change the behavior of cancerous 
cells, perhaps enhancing their resistance to chemotherapy and radiotherapy.  For instance, ECM 
components hyaluronan and fibronectin have been found to accentuate chemoresistance in 
multiple myeloma[32]. These two examples are simply a sampling of the diverse literature 
supporting a role of the extracellular matrix in controlling cellular response to extracellular 
molecules.  Extracellular matrix moieties have been shown to modulate many other cellular 12 
 
behaviors including migration, ligand expression and many different internal signaling processes 
including acting on Rho GTPases and MAPK pathway[33][34][35]. 
  Clearly, a wealth of evidence in diverse models exists to illustrate the role of adhesion 
substrate in controlling cellular proliferation and cellular response to secreted ligands[30].  
Because of the importance of these behaviors in siRNA delivery efficacy, it is logical to theorize 
that the adhesion substrate may also affect siRNA delivery efficacy via these mechanisms.  The 
goal of this project is to examine this hypothesis.    
Alginate hydrogels as controllable cellular adhesion substrates 
  The proposed investigation on the relationship between adhesion substrate and siRNA 
delivery efficacy requires a suitable model system.  Alginate hydrogels offer a well-validated 
choice as a model substrate for the proposed experimental questions due to their controllable 
chemical and mechanical properties[36]. 
  Hydrogels are a vast class of biomaterials with applications spanning clinical, basic 
science and industrial settings.  Broadly speaking, hydrogels are defined as polymeric networks 
that, due to their hydrophilic nature, adsorb a large quantity of water.  As result, they are often 
soft and flexible, with properties that can mimic human tissues.  The polymeric component of a 
hydrogel may be either synthetic or naturally derived.  Alginate is of the latter type, extracted 
from brown seaweed.  Polymers of alginate have a distinctive structure, composed of (1-4)-
linked beta-D-mannuronic acid (M units) and alpha-L-guluronic acid (G units).  Alginate is a 
block polymer, which means that alginate polymers are composed of extended stretches of only 
M units joined to a stretch of only G units.  Divalent ions, most often Ca
2+, can be used to 
ionically bind G-blocks between adjacent alginate chains.   These ‘divalent bridges’ result in the 13 
 
solidification of alginate solutions and hydrogel formation[36].  Other methods to form bridges 
between alginate chains have also been explored, including covalent conjugation[37]. 
  The low cost, relative ease of gel formation and biocompatibility of alginate hydrogels 
has made them attractive materials for medical applications.  However, alginate itself is highly 
resistant to protein adsorption because of its highly hydrophilic surfaces[38].  As discussed 
previously, cellular adherence is critical for many cell type’s survival and proliferation.  Thus, 
alginate hydrogels alone are not good cellular adhesion substrates[36].  To remedy this, much 
effort has been undertaken to modify alginate hydrogels with ligands in order to support cellular 
attachment and thus, normal growth.  Most significant among these modifications is the addition 
of specific cell adhesion molecule RGD peptides[39][29].  Via this approach, aqueous 
carbodiimide chemistry is used to covalently attach primary amines of RGD peptides to free 
carboxyl groups on the alginate[29].  RGD modified alginate polymers, in contrast to their non-
modified forms, are able to support cell attachment, growth and proliferation.  As a result, they 
have been used in many studies, including those that examine the fundamental properties 
governing cell/adhesion substrate interactions [29][39][36]. 
  A major advantage of RGD-modified hydrogels for use in this investigation is that they 
allow for control of both chemical and mechanical properties of interest.  In terms of the 
chemical properties, modifications of the RGD chemical crosslinking procedure allows for 
modulation of the density of RGD molecules on the alginate surface.  Changes in RGD density 
can alter the number of cellular receptor (integrin) and adhesion substrate (RGD ligand) 
interactions.  As discussed previously, integrins provide a key mechanism by which cells interact 
with their microenvironment and then translate environmental signals intro intracellular 
biochemical cascades.  Thus, the density of RGD ligands on a surface presents a control point for 14 
 
understanding cell/material interactions[30].  In terms of the mechanical properties, by altering 
the concentration of Ca
2+ used in the alginate crosslinking procedure, it is possible to change the 
stiffness of the gel.  Increasing Ca
2+ crosslinker results in a stiffer gel[29].  As discussed 
previously, this represents a second important control point for cell/materials interactions, since a 
variety of studies have shown that adhesion substrate stiffness plays a key role in cellular 
proliferation, differentiation and other behaviors.  In this work, alginate will thus be used as an 
adhesion substrate that can be manipulated to examine the role of RGD density and stiffness of 
siRNA delivery efficacy. 
Regulation of DNA delivery efficacy by adhesion substrate modification 
  There is precedent to believe that adhesion substrate can alter siRNA delivery efficacy, 
because it has been shown to alter the delivery of other nucleic acids.  Early experiments have 
demonstrated that ECM composition can change gene expression mediated by plasmid DNA 
delivery.  Specifically, fibronectin exposure was demonstrated to enhance both cellular 
proliferation and gene expression of exogenously introduced plasmid DNA [40][41][42].  
Because plasmid DNA requires introduction into the nucleus for expression and fibronectin 
increased proliferation, it was thought that the nuclear membrane breakdown occurring during 
the increased proliferation mediated the increased gene expression[43][44].  Further work was 
undertaken by the Mooney Lab to more systematically examine the factors regulating adhesion 
substrate control of gene expression.  In these experiments, RGD alginate hydrogels were used to 
provide RGD density and stiffness modifiable adhesion substrates.  The plasmids used to 
transfect the cells were delivered as a noncovalent complex with cationic polymer 
polyethylenamine (PEI).  Interestingly, increased RGD density and increased mechanical 
stiffness of the alginate hydrogels were able to independently increase gene expression of 15 
 
adherent pre-osteoblast cells.  Increases in gene expression correlated with increased cellular 
proliferation on these adhesion substrates suggesting that again, increased plasmid access to the 
nucleus due to nuclear membrane breakdown during mitosis may be the mechanism by which 
increased gene expression occurs[30][23]. 
  Although siRNA is still a nucleic acid, its mechanism of action does not require nuclear 
entry[9].  Thus, it is of interest to explore how the same adhesion substrate factors that influence 
DNA gene expression can also alter siRNA expression. 
Aims of study 
  siRNA presents a potentially revolutionary class of clinically effective therapeutics.  
However, like other biomacromolecule therapeutics, delivery of siRNA remains a major barrier 
to its use.  Although much research has focused on optimizing the delivery vehicles for siRNA, 
considerably less is known regarding the influence of cellular adhesion substrate on siRNA 
mediated protein silencing.  Based upon the above background evidence, it is hypothesized that 
altering the properties of cellular adhesion substrates can alter siRNA delivery efficacy.  
Towards evaluation of this hypothesis, alginate cellular adhesion substrates will be generated 
with alterations in two variables: adhesion substrate RGD ligand density and substrate stiffness.  
These variables and the range of values for these variables were chosen because they have 
previously been shown to alter the delivery efficacy other nucleic acid compounds[30].  
Subsequently, siRNA mediated knockdown of enhanced Green Fluorescent Protein (eGFP) 
expression in a stably transfected eGFP U251 (human glioma) cell line seeded on the different 
alginate substrates will be assessed to determine siRNA delivery efficacy.  U251 cells were used 
because siRNA therapeutics may be a valuable intervention for gliomas which remain without 16 
 
good treatment options despite being highly invasive tumors with poor prognoses. The 
progression of this work can be broken in to three major aims. 
 
1)  Synthesize and characterize a series of alginate adhesion substrates.  A series of 
alginate polymers with variations in either the elastic modulus or the extent of RGD 
integrin ligand density will be synthesized.  Values for the elastic moduls and RGD 
density will approximate those used in previous studies examining the effect of 
substrate on other types of nucleic acid delivery[30].  Subsequently, these adhesion 
substrates will be characterized prior to cellular seeding. 
 
2)   Investigate the growth and behavior of cells grown on the alginate adhesion 
substrates synthesized.  Differences in number and surface area of cells grown on 
the substrates generated in Aim 1 may alter the ability of siRNA to be endocytosed 
and delivered to the cytoplasm.  Thus, prior to determining siRNA knockdown 
efficacy, analysis of the cellular properties that could alter siRNA delivery will be 
examined. 
 
3)  Evaluate the siRNA delivery efficacy in U251 cells cultured on the alginate 
adhesion substrates.  To determine the ability of adhesion substrate to alter non-viral 
siRNA delivery, the efficacy of targeted fluorescent protein knockdown after siRNA 
administration for cells grown on varying alginate adhesion substrates will be 
evaluated.  Uptake of fluorescently labeled siRNA on different substrates will also be 
examined to further explore any changes in siRNA knockdown efficacy. 17 
 
MATERIALS AND METHODS 
 
Materials 
  Dulbecco's modified Eagles' medium (DMEM), fetal bovine serum, penicillin, 
streptomycin, Lipofectamine 2000, Trypsin/Ethylenediaminetetraacetic acid (EDTA) and 
Optimem I medium were purchased from Invitrogen (Carlsbad, CA).  Geneticin, 2-(N-
morpholino)ethanesulfonic acid (MES) buffer, activated charcoal, and EDTA were purchased 
from Sigma Aldrich (St. Louis, MO).  N-Hydroxysulfosuccinimide and 1-ethyl-3-3-
dimethylaminopropyl carbodiimide (EDC) were obtained from Pierce Chemical (Rockford, IL).  
MWCO 2500 Dialysis Membranes were obtained from Fisher Scientific (Pittsburg, PA). 
Ultrapure MVG alginate was purchased from FMC Biopolymer (Princeton, NJ). RGD peptide 
G4RGDASSKY-OH was supplied by Peptides International (Louisville, KY). SiRNA was 
obtained from Integrated DNA Technologies (Coralville, IA).  Alexafluor488 labeled siRNA 
was purchased from Qiagen (Valencia, CA). 
 
Alginate hydrogel synthesis 
The synthesis and mechanical characterization of RGD-modified alginate hydrogels was 
performed according to a previously described procedure [29][45]. Briefly, alginate polymers 
were covalently conjugated to RGD peptides via EDC/SulfoNHS coupling to yield differing 
numbers of RGD peptide per alginate polymer (degree of substitution). For example, a gel with 
an average of two RGD ligands per alginate macromolecule via a previously validated synthesis 
scheme was designated DS 2[29]. Calcium crosslinking was employed to form hydrogels from 
RGD-modified alginate.  Subsequently, the elastic moduli of gels were adjusted by controlling 
the concentration of calcium used to form the gels.  In this study, four categories of ionically 
crosslinked alginate hydrogels were generated for use as cellular adhesion substrates, 
summarized in Table 1. 18 
 
 
Cell Culture 
Yong Choi and John Park (NINDS, Bethesda, MD) generously provided human 
malignant glioma U251 cells stably expressing enhanced green fluorescent protein (eGFP) via 
electroporation transfection with the pEGFP-c1 cDNA plasmid.  Limited dilution cloning was 
undertaken to yield a narrow range of eGFP expression level in clonal populations of eGFP 
expressing U251 cells.  DMEM supplemented with 10% fetal bovine serum, 100 μg/mL 
penicillin, 100 IU streptomycin and 1 mg/mL geneticin was used as cellular media.  The 
geneticin was added to maintain eGFP expression via the pEGFP-c1 plasmid’s geneticin 
resistance cassette.  Cells were passaged biweekly with Trypsin/EDTA, and maintained in a 
37°C humidified, 5% CO2 incubator. 
 
Quantification of cell growth, surface area and numbers 
Four types of alginate gels were prepared with systematic variation in RGD density and 
elastic modulus as described in Table 1.  Gels were formed with a 1 mm thickness and 10 mm 
diameter.  Prior to cell seeding, the gels were incubated in 0.5 mL of complete DMEM growth 
medium overnight in a 37°C humidified, 5% CO2 incubator.  A single gel was then transferred 
into one well of a 24-well plate.  Subsequently, 6 x 10
4
 cells/0.5 mL of growth media was added 
to each well to seed the gels.  Fluorescent imaging was performed with a Nikon Eclipse E800 
fluorescent microscope and Nikon camera attachment.  Analysis of surface area distributions and 
cell number recorded in the fluorescent images was done with ImageJ (NIH, Bethesda, MD). 
 
Evaluation of siRNA-mediated eGFP knockdown  
Clonal eGFP U251 cells were cultured on alginate gels as described in the previous 
section, with the exception that media used was antibiotic free DMEM supplemented with 10% 
fetal bovine serum.  Cells were allowed to incubate overnight in a 37°C humidified, 5% 19 
 
CO2 incubator prior to the addition of siRNA complexed to Lipofectamine 2000 at various 
concentrations to each well of the 24 well plate.  The siRNA sequence for silencing eGFP is as 
follows: sense-GCAGCACGACUUCUUCAAGTT, antisense- 
CUUGAAGAAGUCGUGCUGCTT.  A scrambled siRNA control has the following sequence: 
sense-GUGACAUCGCGACCACUUATT, anti-sense-UAAGUGGUCGCGAUGUCACTT 
(Integrated DNA Technologies, Coralville, IA).  Non-siRNA containing medium within each 
was aspirated, and siRNA-Lipofectamine 2000 complexes suspended in 100 μL of OptiMEM I 
were added per well.  The complexes were incubated with the cells on the alginate hydrogels for 
4 hours prior to removal of the complex containing media and replacement with 500 μL of 
complete growth DMEM medium.  Cells growing on the alginate gels were then allowed to 
incubate for a further 72 hours at 37°C and 5% CO2.  After completion of this incubation time, 
gels and their adherent cells were transferred from their wells into 1 mL of 50 mM EDTA in 
phosphate buffered saline (PBS) for 15 min to allow the alginate gels to dissolved.  The 
remaining cells were pelleted and resuspended in 300 μL D-PBS.  The suspended cells were then 
filtered through a cell strainer into a fluorescence-activated cell sorting (FACS) tubes for use 
with the LSR Fontessa (BD software via forward scatter/side scatter gating (FSC/SSC) to isolate 
viable cells.  Further analysis of fluorescent expression was performed with FlowJo V.6 software 
(TreeStar Inc., Ashland, OR). 
  
Evaluation of siRNA uptake 
Fluorescent AlexaFluor488 labeled siRNA was used to assess siRNA uptake.  The 
procedure for siRNA uptake was similar to that described for the eGFP silencing siRNA and 
scrambled siRNA control.  However, FACS analysis was done earlier to evaluate for uptake 
directly after wash-out of the siRNA-Lipofectamine 2000 complexes on day 1 post-seeding of 6 20 
 
x 10
4 cells/0.5 mL of growth media.  Concentration of AlexaFluor488 labeled siRNA was held 
constant at 50 nM for uptake experiments.  Uptake was determined by comparing the mean 
fluorescent intensity at 488 nm wavelength for cells receiving AlexaFluor488 labeled siRNA and 
untreated control cells.  
 
Statistical analysis 
SPSS 17.0 (SPSS, Chicago, IL) was used to assess for significance via one-way analysis 
of variance (ANOVA) with post-hoc Scheffe test.  Student t-tests were done with Excel 2007 
(Microsoft, Redmond, WA). 
 
   21 
 
RESULTS 
Synthesis and characterization of alginate hydrogels 
Alginate hydrogels were synthesized with systematic variation in RGD peptide density 
and elastic modulus as shown in Table 1.   There were two levels of RGD density achieved via 
covalent conjugation to yield a ratio of RGD ligand to alginate polymer of either 2 or 16 
(referred to subsequently as the degree of substitution or DS).  An example of a typical hydrogel 
appearance is shown in Figure 1.   
These gels maintained their mechanical stiffness over the time course of experiments 
used in subsequent studies, as shown in Figure 2A.  At day four of incubation, the two gels types 
synthesized with 50 mM and 100 mM Ca
++ had elastic moduli of 53 ± 23 kPa and 133 ± 31 kPa, 
respectively.  Covalent modification did not alter the mechanical properties of the hydrogel, as 
shown in Figure 2B.   
 
eGFP U251 cell growth characteristics on alginate substrates 
The growth of U251 cells on the alginate adhesion substrates was characterized in terms 
of cell morphology, proliferation and surface area.  Alginate hydrogel substrates used had either 
DS 2 or DS 16, with an elastic modulus of either 53 or 133 kPa.   Cells adhered to all four 
categories of gel without dramatic variations in cellular morphology (Figure 3).  However, there 
were a higher number of cells grown on alginate substrate had an elongated shape compared to 
those grown on tissue culture polystyrene (TCPS) as seen in Figure 3.    
  There was an initial significant difference between the mean surface area of cells grown 
on the 53 kPa DS 2 alginate gel when compared to 133 kPa DS 16 alginate gel on day 1 post-
seeding.  Average surface areas for the DS 2 alginate gels with elastic moduli of 53 kPa and 133 
kPa were 340 and 314 µm
2, respectively.   Cells adherent to the DS 16 substrates possessed 
slightly larger average surface areas of 388 and 432 µm
2 for 53 kPa and 133 kPa, respectively.  22 
 
Finally, TCPS adherent cells had the largest average surface area of 519 µm
2.   There were no 
significant differences in cellular surface area for cells grown on the four different alginate 
substrates the fourth day after seeding, as seen in Figure 4.   
  Cell number was also measured for cells growing on each of the alginate adhesion 
substrates.  Total cell number was greatest for the alginate gels with the highest degree of 
substitution or RGD density, as seen in Figure 5A.  However, after normalization by the number 
of cells present at day 1 after seeding, there was no difference in cell number amongst substrates, 
as seen in Figure 5B. 
 
siRNA gene silencing efficacy on alginate substrates of varying RGD densities and elastic 
moduli 
The effect of variations in alginate hydrogel substrate RGD density and elastic modulus on 
siRNA silencing efficacy in eGFP expressing U251 cells was assessed via quantification of 
fluorescence intensity.  On the TCPS control surface, U251 cells exposed to 8.25 nM of siRNA 
designed to specifically silence eGFP complexed with Lipofectamine 2000 had a 44 ± 3% 
decrease in eGFP expression, as seen in Figure 6.  However, the same cells grown on alginate 
adhesion substrates did not show knockdown efficacy of siRNA at this concentration, also seen 
in Figure 6.  A scrambled siRNA control showed no significant eGFP expression knockdown for 
U251 cells grown on TCPS under the same conditions, as seen in Figure 7.   
At a higher concentration of 33 nM siRNA, the knockdown effect on cells adherent to 
TCPS resulted in a higher knockdown effect of 80 ± 2%, as seen in Figure 6.  This effect was 
predominately sequence specific because a scrambled siRNA control demonstrated only a 9% 
knockdown in eGFP expression, as seen in Figure 7.  At this higher concentration of siRNA, 
there was a significant siRNA knockdown effect for cells adherent on the alginate substrates, 
although the amount of knockdown effect was less than for the TCPS substrate.  Normalization 23 
 
the knockdown percentage for TCPS and the different alginate substrates by cell surface area one 
day after seeding eliminated the difference in siRNA knockdown efficacy between TCPS and 
some, but not all, of alginate substrates.   
The gel with the highest mechanical rigidity of 133 kPa and highest RGD content of DS 16 
showed the highest amount of siRNA mediated knockdown.  eGFP expressing cells grown on 
these alginate gels showed a 52 ± 12% knockdown of eGFP expression when exposed to 33 nM 
of siRNA.  The softer gel with 53 kPa elastic modulus and the same RGD content with DS 16 
demonstrated a similar 47 ± 14% knockdown effect.   
Reducing the DS from 16 to 2 while keeping the elastic modulus high at 133 kPa resulted in 
a significant decrease in knockdown efficacy.  This eightfold decrease in RGD density reduced 
the knockdown efficacy of the siRNA by 52% to 25 ± 10%.  The softer gel with elastic modulus 
of 53 kPa and a low RGD density with DS 2 showed the lowest knockdown efficacy of 34 ± 6%.   
Quantification of siRNA uptake on different alginate substrates 
  Cells grown on the different alginate substrates were also evaluated for differences in 
siRNA uptake.  The increase in fluorescence signal from non eGFP expressing U251 cells 
exposed to fluorescently labeled (AlexaFluor 488) siRNA at one day after seeding was highest 
for cells grown on TCPS, as seen in Figure 8A.  Among the alginate gels, the cells growing on 
the gels with the highest RGD density had the greatest siRNA uptake.  Relative measurements of 
siRNA uptake were used to normalize the increased silencing efficacy of cells grown on the 
alginate substrates.  Normalization by siRNA uptake eliminated the significant increase in 
siRNA silencing efficacy seen for between the 133 kPa/DS 2 gel and the 133 kPa/DS 16 gel, as 
seen in Figure 8B.  There was no significant difference in uptake between cells growing on the 
133 kPa gels versus the 53 kPa gels when the RGD density was held constant. 
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DISCUSSION 
Synthesis and characterization of alginate hydrogels 
  Prior studies have shown that calcium crosslinked alginate hydrogels can decrease in 
stiffness over time.  This occurs as the crosslinking calcium ions that hold together the guluronic 
acid (G) blocks of alginate polymers exchange with monovalent ions from the incubating 
media[46]. Because one of the goals of the presented experiments was to evaluate the siRNA 
silencing ability on alginate gels with varying mechanical stiffness, it was important to ensure 
that the mechanical stiffness of the alginate gels remained constant over the time course of 
subsequent experiments.  Determination of the elastic modulus over the maximum time course of 
four days used in these studies showed that stiffness of the gels did not vary significantly over 
time, as seen in Figure 2A.  Furthermore, covalent modification of alginate polymers with RGD 
did not appreciably alter the mechanical properties of hydrogels made with these modified 
alginates, as seen in Figure 2B. 
 
eGFP U251 cell growth characteristics on alginate substrates 
Hydrogels formed from unmodified alginate polymers do not allow for mammalian cell 
adhesion, and modification of the alginate with RGD is one way to promote cellular 
adhesion[47].  However, there is often a cell type dependent threshold limit of RGD grafting 
density, below which a particular cell type does not adhere to the alginate hydrogels[47][48].  
Thus, it was of interest to characterize U251 cell morphology, proliferation and surface area on 
the alginate hydrogels prior to evaluating siRNA knockdown efficacy. 
    Cells were able to adhere to gels of both DS 2 and DS 16 RGD densities, as seen in 
Figure 3.  General observations of the eGFP expressing U251 cells’ morphology did not 
appreciably differ between the different alginate substrates.  However, the cells grown on the 
alginate gels did have a more enlongated appearance compared to cells grown on TCPS, as seen 25 
 
in Figure 3.  This may be due to a higher density of adsorbed adhesion molecules or stiffer 
substrate of the TCPS compared to the alginate gels resulting in the more flattened and spread 
out morphology of cells grown on TCPS. 
  Qualitative observations of cell shape were followed up by quantitative evaluation of cell 
surface area for each of the four alginate gel types and TCPS.  Cell surface area was measured 
because theoretically, variations in cell surface area might change the opportunities for siRNA 
particle internalization and thus, the efficacy of siRNA knockdown.  However, there were few 
differences in cell surface area among the different alginate growth substrates at day 1 after 
seeding.  The 53 kPa and DS 2 alginate gel had a significantly smaller surface area compared to 
the 133 kPa and DS 16 alginate gel.  In contrast, the surface area of cells grown on the TCPS 
substrate was significantly larger than any of the alginate substrates, supporting the observation 
of less enlongated and more spread out cells on the TCPS substrates. 
  Previous studies have shown that substrates permitting increased cellular proliferation 
facilitate increased delivery efficacy of DNA/PEI complexes[49][30].  It is possible that a similar 
effect might occur for siRNA delivery, hence measurements of the U251 cellular proliferation on 
the different alginate growth substrates was estimated by counting cell number at different time 
points post-seeding.  Although cell number does conflate rates of cell proliferation and death, 
during the time course studied, cells grown on the substrates were subconfluent and supplied 
adequate nutrients making it unlikely that cell death was a substantial contributor to the total cell 
counts.   
  Although the total cell number was highest at day four post-seeding on the gels with the 
highest RGD density (DS 16), normalization to the number of cell present on the first day post 
seeding eliminated the significant difference in cell number for the higher RGD density 26 
 
substrates.  This supports the conclusion that although there might be different numbers of cells 
initially adherent to the different substrates, cell proliferation was not necessarily increased by 
differences in substrate properties. 
  These findings are in contrast to observation in other work were cells have responded to 
increased growth substrate stiffness and RGD density with increased rates of proliferation.  
However, these experiments were done in myoblasts and hepatocytes, so it is possible that the 
presented experiments differences from previous findings are due to a difference in cell 
type[39][47][48].  In particular, the U251 cell type is derived from human glioma tissue, and as a 
neoplastic cell line may be under reduced proliferative control by its adhesion substrate.  
Alternatively, the U251 cell line may be responsive to a different range of elastic moduli of the 
substrate compared with myoblasts and hepatocytes. 
 
siRNA gene silencing efficacy on alginate substrates of varying RGD densities and elastic 
moduli 
  After characterizing the growth characteristics of U251 cells on the various alginate 
substrates, the effect of these substrates on siRNA gene silencing efficacy was tested.  For these 
experiments, it was presumed that eGFP protein levels reflected eGFP mRNA levels, and that 
effective siRNA silencing would decrease both protein and mRNA amounts even though only 
the protein levels were examined.   
  The siRNA used was verified for sequence specificity by testing eGFP expression for 
cells exposed to both sequence-specific siRNA against eGFP and a scrambled siRNA control, as 
seen in Figure 7.  The sequence specific siRNA was then used to evaluate for siRNA mediated 
knockdown on the different growth substrates. 
  Results from the siRNA experiements presented in Figure 6 showed the range of elastic 
moduli tested (53-133 kPa) did not significantly impact the efficacy of siRNA knockdown in 27 
 
U251 cells.  This finding contrasts with previous results demonstrating a change in DNA 
delivery measured by exogenously induced DNA expression in preosteoblasts dependent on the 
stiffness of alginate growth substrates[30].  The presented experiments cannot definitively 
identify the mechanistic reason for a lack of this effect in present experiments.  It is possible that 
differences in cell lines can result in differences in the range of elastic moduli that elicit a 
functional response.  Most organs and tissues have a modulus range from 0.1 to 100 kPa, and the 
alginate substrates used in the presented experiments have elastic moduli that overlap this range.  
However, the U251 cells used may require further testing at an increased range of substrate 
stiffness to reveal changes in siRNA efficacy because they may not be responding to changes in 
adhesion substrates over the range of 53-133 kPa.  As discussed previously with regard to 
proliferation patterns on the different substrates, it is also possible that U251 cell line’s origin 
from human neoplastic tissue may make these cancer cells less responsive to extracellular matrix 
cues than non-neoplastic cell lines.   
  The TCPS substrates showed the highest efficacy of siRNA knockdown when used as a 
growth substrate.  Perhaps these substrates’ highest elastic moduli resulted in the increased 
silencing efficacy.  Yet, TCPS has a different composition and surface character than alginate 
gels, and thus, it is impossible to exclude other properties of TCPS besides stiffness that may be 
altering siRNA efficacy. 
  Unlike alteration in elastic modulus, RGD density of the alginate substrates did 
significantly alter the siRNA mediated protein knockdown.  The alginate substrates with the 
highest RGD density had the highest levels of siRNA mediated knockdown, as apparent from the 
increase in siRNA efficacy for cells grown on the DS 16 alginate gels compared to the DS 2 
alginate gels both with 133 kPa elastic modulus, as seen in Figure 6. 28 
 
  This difference in siRNA silencing efficacy is unlikely to be due to changes in the ratio of 
cell number to siRNA concentration, because the day one post-seeding density of U251 cells on 
the DS 2 alginate gels did not significantly differ from that on the DS 16 alginate, as seen in 
Figure 5.  In addition, differences in cell surface area or morphology were not observed between 
the DS 2 and DS 16 gels, as seen in Figures 3 and 4, so it is unlikely that these factors accounted 
for the different RGD density mediated protein silencing effects observed.   
  In contrast to the findings for alginate gels, there was a statistically significant increase in 
both cell surface area and knockdown efficacy for cells grown on the TCPS substrate as 
compared to alginate substrates, as seen in Figure 6.  The finding that normalization of the 
knockdown percentage for TCPS and the different alginate substrates by cell surface area one 
day after seeding eliminated the difference in siRNA knockdown efficacy between TCPS and 
some, but not all, of alginate substrates suggests a correlation between changes in cell surface 
area and knockdown efficacy of siRNA.  However, the fact that even after normalization for 
surface area, there was still a significantly increased siRNA knockdown efficacy for cells grown 
on the TCPS substrates and some of the alginate substrates suggests that surface area alone does 
not account for all of the difference in substrate effects.   
Quantification of siRNA uptake on different alginate substrates 
  Further investigation into possible mechanisms of the increased siRNA knockdown 
efficacy was pursued by evaluating differences in siRNA uptake for cells grown on the different 
alginate substrates.  The cells grown on alginate substrates with the highest RGD density 
demonstrated the highest siRNA uptake.  In addition, normalizing for siRNA uptake eliminated 
the significant difference in siRNA silencing efficacy seen between the 133 kPa gels of either DS 
2 or DS 16.  This result suggests a correlation between increased siRNA uptake, increased 
siRNA silencing efficacy and increased RGD density of the substrate.  However, this result does 29 
 
not distinguish which part of the endocytotic pathway is upregulated.  Endocytosis is a multi-step 
process involving a variety of steps including formation of vesicles, trafficking of intracellular 
substances and release of cargo from vesicles[50].  More research is required to identify which 
exact uptake steps are affected by the increased substrate RGD density.  Furthermore, these 
results do not preclude other mechanisms by which RGD density may modulate siRNA 
knockdown efficacy.  Other possibilities include RGD density mediated changes in endogenous 
siRNA silencing protein effector complexes and/or increased intracellular siRNA stability. 
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CONCLUSIONS 
  The findings of this thesis demonstrate that adhesion substrate properties can alter the 
efficacy of exogenously delivered siRNA.  Human glioma U251 cells were successfully grown 
on alginate hydrogels of varying elastic moduli and RGD density without qualitative difference 
in morphology or quantitative differences in surface area or cell number.  However, increasing 
the RGD density of alginate hydrogel substrates was able to increase the efficacy of siRNA 
knockdown at a 33nM concentration of siRNA.  Alterations in elastic moduli of the alginate gels 
over the 53-133 kPa range tested did not alter siRNA efficacy.  A lower siRNA concentration of 
8.25 nM did not induce siRNA mediated protein knockdown for any of the alginate adhesion 
substrates tested, despite the ability of this concentration to cause knockdown for cells grown on 
TCPS.  Furthermore, cells grown on TCPS responded with more siRNA mediated protein 
knockdown than any of the experiments involving alginate substrates.  Increases in siRNA 
uptake were correlated with increased siRNA-mediated protein knockdown for both TCPS and 
alginate substrates.  Overall, the results of this work indicate that adhesion substrate properties 
can alter the cellular response to siRNA.  This has implications for pre-clinical testing of siRNA-
based therapeutics in which cells are often grown on a variety of substrates that may be different 
than the extracellular environment of the in vivo target cell.  
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SUGGESTIONS FOR FUTURE WORK 
The findings presented in this thesis provide several avenues for future investigation.  
Two broad areas for further work include assessing the generalizability of adhesion substrate 
control and mechanistic investigation into siRNA delivery efficacy.  Each of these directions will 
be discussed below with suggestions for continued experimental approaches. 
 
Exploring the generalizability of adhesion substrate control of siRNA delivery efficacy 
  The presented results demonstrate that alteration of RGD density on alginate substrates 
can modify the efficiency at which siRNA can silence an exogenously introduced gene.  One of 
the limitations of the current work is its use of a single siRNA delivery agent, a single gene 
target, a single cell type and two types of adhesion substrates.  Further work is needed to 
determine if the findings presented here are generalizable effects across cell type, siRNA gene 
target, siRNA delivery vector composition and adhesion substrate.   
Exploration in different in vitro models would be able to determine whether the results 
presented here are a special case scenario, or instead, broadly representative of adhesion 
substrates’ role in controlling siRNA efficacy.  Testing the role of cell type is straightforward.  
Extensive research has been performed with myocytes and pre-osteocytes on alginate substrates.  
Thus, one could easily grow either cell type on the range of alginate substrates described here, 
and expose them to siRNA designed to silence a particular gene product.  It would be interesting 
and useful to compare the response characteristics of neoplastic cell lines, like the U251 cells 
used in this work, with non-neoplastic cells lines.  Difference in responses could have 
implications for the pre-clinical testing of siRNA, since siRNAs are being considered as possible 
anti-cancer therapeutics[15] [18][51][52].  A better understanding of the adhesion substrate 
response of neoplastic cells to siRNA may lead to the development of more realistic in vitro 
models for anti-cancer siRNA therapeutic screening. 32 
 
In addition, the current work was limited by testing the knockdown of only a single gene, 
eGFP, chosen for the ease of measuring expression knockdown.  Further work could expand the 
siRNA targeted genes beyond exogenous markers, like luciferase or GFP, to other more 
physiologically relevant gene products.  Depending on the gene silenced, various methods could 
be used to quantify siRNA mediated knockdown on the different substrates including qRT-PCR 
or Western blotting.   
U251 cells did not show changes in siRNA knockdown efficacy over the range of elastic 
moduli tested in these experiments.  It would be informative to expand the range of alginate 
stiffness tested to determine if U251 cells are just less responsive to their extracellular 
environment or if they respond to a different range of stiffness than tested in these experiments.  
Also, it would be useful to determine whether the results regarding RGD density hold true for 
substrates other than alginate.  Other adhesion substrate hydrogels like PEG, that are both 
normally non-cell adherent could be controllably functionalized with RGD to see if they yielded 
similar increased siRNA knockdown efficacy for increases in RGD density[34].  This would 
allow for further explorations of the adhesion substrates’ role in siRNA delivery efficacy, outside 
of the parameters tested in this work. 
Finally, although Lipofectamine 2000 was chosen as a delivery agent for this work due to 
its widespread use in the laboratory setting, its high cytotoxicity limits its use in clinical 
applications[53][54].  There are a wide variety of other siRNA delivery agents in current 
development including polymers, peptides and lipids[20][22][55][56][57].  It would be useful to 
determine if the increased siRNA knockdown efficacy observed for the Lipofectamine 2000 
complexed siRNA also occurred for other modes of siRNA delivery. 
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Expanding on the current investigation of the effects of growth substrates into the three 
dimensional environment 
  The major motivation for the current work is to improve our understanding of how the 
microenvironment of cells can alter their response to siRNA, in order to determine if 
investigators should be considering cell adhesion substrate when choosing appropriate pre-
clinical models for evaluation of siRNA as therapeutic.  However, the use of two dimensional 
adhesion substrates is an approximation of cell growth in vivo, as most clinically relevant cell 
types normally grow within a three dimensional microenvironment. 
  Much recent work has shown that cell behavior can be altered by a more physiological 
three dimensional microenvironment, as opposed to the traditional two dimensional tissue culture 
substrates[58][59].   Thus, it would be useful to extend the work done here in a two dimensional 
microenvironment exploring the role of RGD density and stiffness to a three dimensional culture.  
This could move the applicability of the findings here to the most current in vitro models for pre-
clinical therapeutic testing.  Alginate would be well suited to this application because it has been 
previously used for growth of cells in three dimensional gel environments[45][60].  
 
Mechanistic investigation into the role of adhesion substrate control of siRNA efficacy 
  From the experiments undertaken, it appears that increased siRNA uptake may play a role 
in the increased siRNA knockdown efficacy seen for alginate gels with higher RGD density.  
However, it would interesting to determine whether the increased siRNA uptake is reflective of 
increased internalization of other compounds.  In addition, it remains unclear whether the 
increased uptake alone is responsible for modulating the siRNA knockdown effect or whether 
there may also be altered activity of the endogenous siRNA silencing protein complexes.   
  Although some uncertainty exists regarding the exact mechanism by which siRNA 
complexed to cationic lipids like Lipofectamine2000 enter cells, most agree that the process is 34 
 
likely endocytosis dependent.  In this work, we observed increased internalization of 
fluorescently labeled siRNA complexed to Lipofectamine2000 in cells adherent to high RGD 
density alginate hydrogels.  These results lead to the question of whether adhesion substrates can 
have more broad affects of endocytosis, not simply affecting siRNA complex uptake, but the 
uptake of other compounds.  Specifically, since it appears that siRNA uptake is enhanced by 
certain adhesion substrates, it would be of interest to determine whether this increased uptake 
extends to other molecules.  Although previous studies have mostly focused on linking adhesion 
substrate increased proliferation with increased delivery of biomacromolecules, it is possible that 
increased rates of endocytosis may also be an important factor in adhesion substrate control of 
biomacromolecule delivery.  Although the study of endocytosis is a complex and rapidly 
evolving field, systematic experimentation to assess endocytotic uptake of different ligands in 
response to variations in adhesion substrate may yield results that provide useful frameworks in 
which to understand the tripartate interaction between cells, their adhesion substrates and 
endocytosed ligands.  Experiments might employ canonical ligands known to be endocytosed by 
specific pathways, e.g. tranferrin in the clathrin dependent pathway or Lactosylceramine in the 
caveolin dependent pathway[61][62].   
  It is also possible that the increase in siRNA efficacy seen on the high RGD density 
alginate adhesion substrates is also influenced by increased activity of the siRNA silencing 
pathway.  As discussed in the introduction, a variety of different enzymes are required for siRNA 
guided destruction of mRNA.  Perhaps changing the adhesion substrate can upregulate protein 
effectors involved in this pathway.  To test this hypothesis, it may be valuable to quantify the 
amount of siRNA effector enzyme  (e.g. RISC) mRNA through PCR or proteins through 35 
 
Western Blotting.  Increases in the siRNA effector enzymes would indicate an increased capacity 
for enacting siRNA mediated protein silencing within the cell. 
  Overall, the presented results within this thesis are provoking, with significant 
implications for preclinical testing of siRNA.  The body presents many examples of cells with 
altered extracellular environments, and application of siRNA as a therapeutic may require 
optimization with regard to cellular adhesion substrate.  Furthermore, increasing the successful 
translation of siRNA therapeutics from the bench to the bedside will only be enhanced by 
elucidation of factors affecting siRNA delivery.  Understanding the generalizability of the 
observed results, as well as the mechanism by which they occur, is critical for the long-term 
importance of the presented findings. 
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SUMMARY 
Short interfering RNAs (siRNAs) are an extremely promising class of therapeutics due to 
their ability to prevent the synthesis of disease causing proteins.  In order to mediate their useful 
effects, siRNAs must be delivered to the inside of cells.  However, delivering enough siRNA 
intracellularly to yield clinically relevant effects poses a major practical challenge.  The 
presented work aims to address this barrier through an enhanced understanding of the factors that 
affect siRNA behavior in cells.  Specifically, it explores the hypothesis that the surface on which 
cells adhere modulates the efficiency of administered siRNA to cause protein synthesis 
inhibition.  To investigate this hypothesis, cells were grown on materials that were systematically 
varied in properties altering cell-surface adhesion.  Increased siRNA efficiency was observed 
when cells were grown on materials designed to increase the extent of cell adhesion.  These 
results demonstrate that the surface on which cells adhere can change cellular response to siRNA 
and introduce an important new variable for consideration in the design of siRNA therapeutics.   
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TABLES AND FIGURES 
 
Redacted. 
 
Table 1.  Four types of alginate hydrogels were synthesized with two different values of RGD 
density and elastic modulus.  DS refers to degree of substitution or the approximate number of 
RGD ligands per alginate polymer. This material is reproduced with permission of John Wiley & 
Sons, Inc. 
 
 
Figure 1.  Photograph demonstrating the typical appearance of an alginate hydrogel.  Scale 
included in photograph corresponds to a length of 2 cm. 
 
Redacted. 
 
Figure 2.  (A) The mean elastic modules of 2% by weight alignate hydrogels with 50 mM (□) 
and 100 mM (■) of calcium crosslinker was measured during a four day incubation period with 
three experiments per value shown.  Error bars represent the standard deviation of the three 
experiments.  Gels synthesized with 50 mM and 100 mM Ca
++ had elastic moduli of 53 ± 23kPa 
and 133 ± 31 kPa, respectively, after four days of incubation.  (B) There was no significant 
difference in mechanical properties of alginate hydrogels without and with a high degree of RGD 
modification.  Hydrogels were formed from 2.0% weight percent alginate and a constant calcium 
cross-linker concentration of 50 mM (53 kPa elastic modulus).  The alginate was either without 
RGD modification (light gray bars) or with DS16 RGD modification (dark gray bars).  Values 46 
 
shown are the mean and error bars are the standard deviation of three experiments.  There were 
no statistically significant differences between the mean elastic values of alginate hydrogels with 
and without RGD modification.  This material is reproduced with permission of John Wiley & 
Sons, Inc. 
 
 
Redacted. 
Figure 3.  Fluorescent imaging of eGFP expressing U251 cells adherent to substrates of varying 
RGD degree of substitution and varying stiffness at 1 day after seeding.  Bar represents 100 μm.  
This material is reproduced with permission of John Wiley & Sons, Inc. 
 
Redacted. 
Figure 4.  Mean surface area measurements of cells adherent to different types of alginate 
substrates over time.  Surface area shown for U251 cells grown on 53 kPa DS 2 alginate gels 
(black), 133kPa DS 2 alginate gels (dark gray), 53 kPa DS16 alginate gels (light gray), 133 kPa 
DS 16 alginate gels (white) and TCPS (striped) at one and four days after seeding.  Mean surface 
area measurements were calculated from the individual surface area measurements for cells 
visible in three 0.58 mm
2 fields on each gel.  Error bars represent the standard deviation among 
average cellular area of each 0.58 mm
2 field.  This material is reproduced with permission of 
John Wiley & Sons, Inc. 
 
Redacted. 
 
Figure 5.  Number of U251 cells present on alginate substrates of varying RGD density and 
elastic moduli over four days.  (A)  Number of adherent cells growing on 53 kPa DS 2 alginate 
gels (black), 133 kPa DS 2 alginate gels (dark gray), 53 kPa DS16 alginate gels (light gray), 133 47 
 
kPa DS 16 alginate gels (white) and TCPS (striped) at either one, two or four days post seeding.  
(B) Data from part A normalized to number of cells present adherent to each gel at day 1 after 
seeding.  Values displayed are the mean cell number and error bars represent the standard 
deviation for four randomly chosen 0.58 mm
2 fields.  This material is reproduced with 
permission of John Wiley & Sons, Inc. 
 
 
Redacted. 
 
Figure 6. Relative eGFP fluorescence expression in U251 cells grown on alginate adhesion 
substrates differing in RGD density (DS or degree of substitution) and mechanical stiffness after 
application of 8.25nM (light gray) and 33 nM (dark gray) of siRNA.  eGFP expression was 
quantified via FACS on more than 50 cells per treatment three days after siRNA application.  
Each knockdown percentage shown represents the mean of three replicate experiments.  Error 
bars represent the standard deviation.  Asterisks indicate statistical significant differences (p < 
0.05) via a student t test either for relationships indicated via a line or in comparison to all other 
treatments of the same siRNA concentration.  This material is reproduced with permission of 
John Wiley & Sons, Inc. 
 
 
Redacted 
 
Figure 7.  Verification that siRNA results in specific targeting of eGFP expression knockdown.  
Normalized fluorescence intensity is shown for stably eGFP expressing clonal populations 
exposed to a sequence specific siRNA (light gray) to a scrambled sequence control siRNA (dark 
gray).  Normalized fluorescence intensity was measured as a ratio between the green 
fluorescence intensity of the cell population when compared to an untreated control.  The above 48 
 
results represent the mean population fluorescent values for a single experiment.  This material is 
reproduced with permission of John Wiley & Sons, Inc. 
 
 
Redacted. 
 
Figure 8.  (A) Fluorescently labeled siRNA uptake for cells grown on different alginate 
substrates normalized by comparison to a non-siRNA treated control.  U251 cells were incubated 
with 50 nM AF488 labeled siRNA for 4 hours before fluorescence uptake was determined by 
FACS analysis on at least 50 cells per treatment.  Shown values are the mean normalized 
fluorescence and error bars represent the standard deviations of three replicate experiments.  
Asterisks indicate significance (p< 0.05) via students t-test for comparisons indicated by a line or 
in comparison to all other treatments.  (B) eGFP expression in U251 cells after exposure to 8.25 
nM  (light gray) or 33 nM (dark gray) anti-eGFP siRNA on alginate adhesion substrates after 
normalization for fold increase in mean fluorescent intensity at 488 nm 1 day after seeding.  
FACS was used to determine the shown mean values of fluorescence intensity 3 days after 
siRNA application for at least 50 cells per treatment and three replicate experiments.  Error bars 
represent the standard deviation for the three replicate experiments.  ANOVA analysis with post-
hoc tests showed no significant difference in knockdown percentage among cells grown on the 
different growth substrates for the same siRNA concentration after normalization for siRNA 
uptake.  This material is reproduced with permission of John Wiley & Sons, Inc. 
 